Secoisolariciresinol diglucoside resolves systemic and skin inflammation in psoriatic mice by ameliorating the gut microbiome and modulating immune responses

Key Points

• The research aims to evaluate the effects of secoisolariciresinol diglucoside on inflammation in a psoriatic mouse model by focusing on gut microbiome and immune response changes.
• Utilized a psoriatic mouse model to test the effects of secoisolariciresinol diglucoside.
• Analyzed changes in gut microbiome composition pre- and post-treatment.
• Assessed systemic and skin inflammation markers to evaluate treatment efficacy.
• Secoisolariciresinol diglucoside significantly improved markers of inflammation in both skin and systemic levels.
• Alterations in the gut microbiome were observed, with beneficial species increasing after treatment.
• Positive modulation of immune responses was noted, correlating with reduced inflammation.